The Lions Eye Institute is an Australian medical research institute affiliated with the University of Western Australia. It was established in 1983 with support of the Lions Clubs of Western Australia and headquartered in the Perth suburb of Nedlands, Western Australia.

During the past decade, Lions Eye Institute conducted 29 clinical trials. In the 10-year time frame, 29 clinical trials started and 7 clinical trials were completed, i.e. on average, 24.1% percent of trials that started reached the finish line to date. In the past 5 years, 14 clinical trials started and 7 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Lions Eye Institute" #1 sponsor was "Hoffmann-La Roche" with 10 trials, followed by "Neurotech Pharmaceuticals" with 4 trials sponsored, "Apellis Pharmaceuticals, Inc." with 3 trials sponsored, "Allergan" with 2 trials sponsored and "Ionis Pharmaceuticals, Inc." with 2 trials sponsored. Other sponsors include 6 different institutions and companies that sponsored additional 15 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Lions Eye Institute" #1 collaborator was "Chugai Pharmaceutical" with 2 trials as a collaborator, "Novotech (Australia) Pty Limited" with 2 trials as a collaborator, "The Lowy Medical Research Institute Limited" with 2 trials as a collaborator, "Adverum Biotechnologies, Inc." with 1 trials as a collaborator and "Allergan" with 1 trials as a collaborator. Other collaborators include 0 different institutions and companies that were collaborators in the rest 10 trials.

According to Clinical.Site data, the most researched conditions in "Lions Eye Institute" are "Geographic Atrophy" (7 trials), "Diabetic Macular Edema" (4 trials), "Diabetic Macular Oedema" (3 trials), "Macular Degeneration" (3 trials) and "Macular Edema" (3 trials). Many other conditions were trialed in "Lions Eye Institute" in a lesser frequency.

Most popular intervention types in "Lions Eye Institute" are "Drug" (24 trials), "Other" (9 trials), "Procedure" (7 trials), "Biological" (4 trials) and "Combination Product" (2 trials). Other intervention types were less common.

The name of intervention was led by "Sham Procedure" (9 trials), "Faricimab" (6 trials), "Aflibercept" (4 trials), "Ciliary neurotrophic factor (CNTF)" (2 trials) and "No intervention" (2 trials). Other intervention names were less common.

The vast majority of trials in "Lions Eye Institute" are 32 trials for "All" genders.

Currently, there are NaN active trials in "Lions Eye Institute". undefined are not yet recruiting, 3 are recruiting, 9 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 14 completed trials in Lions Eye Institute, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Lions Eye Institute, 4 "Phase 1" clinical trials were conducted, 15 "Phase 2" clinical trials and 14 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".